ArticleCancers2010
PCA3 and TMPRSS2-ERG: Promising Biomarkers in Prostate Cancer Diagnosis.
Article in Cancers, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.
- The research progress on diagnostic indicators related to prostate-specific antigen gray-zone prostate cancer.BMC cancer · 2025Pooled it
- Present status of prostate cancer diagnosis, limitations, challenges, and future endeavors.Annals of medicine · 2026Review
- Fluorescent bionanosensor for picomolar detection of biomarkers in fluids.European biophysics journal : EBJ · 2026Article
- Diagnosis of Prostate Cancer: A Comparative Evaluation of Biological Techniques.Diseases (Basel, Switzerland) · 2026Review
- A multi-gene urinary extracellular vesicle mRNA panel as a non-invasive biomarkers for prostate cancer detection.Scientific reports · 2026Article
- Overexpression of the ERG oncogene in prostate cancer identifies candidates for PARP inhibitor-based radiosensitization.The Journal of clinical investigation · 2026Article
- New biomarkers and multiplex tests for diagnosis of aggressive prostate cancer and therapy management.Frontiers in oncology · 2025Review
- Predicting prostate cancer progression with a Multi-lncRNA expression-based risk score and nomogram integrating ISUP grading.Non-coding RNA research · 2024Article
- Putting comprehensive genomic profiling of ctDNA to work: 10 proposed use cases.The journal of liquid biopsy · 2024Review
- Prognostic value of E‑26 transformation‑specific‑related gene in prostate cancer based on immunohistochemistry analysis.Oncology letters · 2023Article
- A New Era of Prostate Cancer Precision Medicine.Frontiers in oncology · 2019Review
- STAT3-induced long noncoding RNAs in multiple myeloma cells display different properties in cancer.Scientific reports · 2017Article
- Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients.Oncotarget · 2017Article
- Molecular and Clinicopathological Aspects of Prostate Cancer in Bulgarian Probands.Pathology oncology research : POR · 2015Article
- Aptamer-based Sandwich Assay and its Clinical Outlooks for Detecting Lipocalin-2 in Hepatocellular Carcinoma (HCC).Scientific reports · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The search for the biomarkers to precisely and non-invasively characterize the biology of prostate cancer (PCa) is the focus of many laboratories across the world. Although prostate-specific antigen (PSA) remains the standard diagnostic tool for PCa, its low specificity leads to unnecessary biopsies in a substantial number of patients. More importantly, with the current status of knowledge, it is very difficult to early identify individuals with a life-threatening disease who require an immediate treatment. The significant advances in genetics and biotechnology in recent years has led to the discovery of new molecular markers including PCA3 and the TMPRSS2:ERG genomic fusion. Both PCA3 and TMPRSS2:ERG, compared to PSA, show an increased specificity in PCa detection. However, the quest for a single PCa marker that can fully satisfy urologists and their patients is still ongoing. The aim of this review is to present the recent findings on PCA3 and TMPRSS2:ERG and to describe their clinical implications and performance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.